WO2008096416A1 - 前立腺がんの悪性度判定キット及びその方法 - Google Patents

前立腺がんの悪性度判定キット及びその方法 Download PDF

Info

Publication number
WO2008096416A1
WO2008096416A1 PCT/JP2007/052025 JP2007052025W WO2008096416A1 WO 2008096416 A1 WO2008096416 A1 WO 2008096416A1 JP 2007052025 W JP2007052025 W JP 2007052025W WO 2008096416 A1 WO2008096416 A1 WO 2008096416A1
Authority
WO
WIPO (PCT)
Prior art keywords
malignancy
prostate cancer
kit
same
gleason
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/052025
Other languages
English (en)
French (fr)
Inventor
Hitoshi Endou
Isao Okayasu
Takeshi Sakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Biomedix Co Ltd
Original Assignee
Fuji Biomedix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Biomedix Co Ltd filed Critical Fuji Biomedix Co Ltd
Priority to CN200780052524A priority Critical patent/CN101680895A/zh
Priority to EP20070713854 priority patent/EP2146208A4/en
Priority to EP15168745.6A priority patent/EP2977761A1/en
Priority to PCT/JP2007/052025 priority patent/WO2008096416A1/ja
Priority to US12/526,062 priority patent/US20100112596A1/en
Priority to JP2008556938A priority patent/JPWO2008096416A1/ja
Publication of WO2008096416A1 publication Critical patent/WO2008096416A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

本発明は、Gleasons分類、TMN分類に加え、新たな診断法である分子マーカーの手法を提供すると共に、手術前の早期段階において生検材料を用いてGleasons分類と組み合わせることによって、手術時に摘出した材料でなく細胞針検査で採取した材料を用いた場合でも、前立腺がんの悪性度がより高精度かつ容易に判定可能な手段を提供することを目的とする、前立腺がんの悪性度を判定（診断）して患者の予後を予測するための判定キット及び判定法に関する。  
PCT/JP2007/052025 2007-02-06 2007-02-06 前立腺がんの悪性度判定キット及びその方法 Ceased WO2008096416A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN200780052524A CN101680895A (zh) 2007-02-06 2007-02-06 前列腺癌的恶性程度判定试剂盒和其方法
EP20070713854 EP2146208A4 (en) 2007-02-06 2007-02-06 KIT FOR DETERMINING THE MALIGNICITY OF PROSTATE CANCER AND METHOD FOR USE THEREOF
EP15168745.6A EP2977761A1 (en) 2007-02-06 2007-02-06 Antibody for determining prostate cancer malignancy
PCT/JP2007/052025 WO2008096416A1 (ja) 2007-02-06 2007-02-06 前立腺がんの悪性度判定キット及びその方法
US12/526,062 US20100112596A1 (en) 2007-02-06 2007-02-06 Kit for deciding degree of malignancy in prostate cancer and method of using the same
JP2008556938A JPWO2008096416A1 (ja) 2007-02-06 2007-02-06 前立腺がんの悪性度判定キット及びその方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/052025 WO2008096416A1 (ja) 2007-02-06 2007-02-06 前立腺がんの悪性度判定キット及びその方法

Publications (1)

Publication Number Publication Date
WO2008096416A1 true WO2008096416A1 (ja) 2008-08-14

Family

ID=39681336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/052025 Ceased WO2008096416A1 (ja) 2007-02-06 2007-02-06 前立腺がんの悪性度判定キット及びその方法

Country Status (5)

Country Link
US (1) US20100112596A1 (ja)
EP (2) EP2977761A1 (ja)
JP (1) JPWO2008096416A1 (ja)
CN (1) CN101680895A (ja)
WO (1) WO2008096416A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012163332A (ja) * 2011-01-28 2012-08-30 J-Pharma Co Ltd 胃癌の悪性度診断用キット
JP2015134778A (ja) * 2015-02-06 2015-07-27 ジェイファーマ株式会社 抗ヒトｌａｔ１モノクローナル抗体及び前立腺がんの悪性度判定キット
JP2018509618A (ja) * 2015-03-11 2018-04-05 ジェイファーマ株式会社 前立腺癌の悪性度を決定するためのキット及び方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141285A1 (ja) * 2011-04-15 2012-10-18 ジェイファーマ株式会社 乳癌のバイオマーカー
CN102866052A (zh) * 2012-10-16 2013-01-09 百奥迈科生物技术有限公司 一种细胞染色试剂盒及其使用方法
WO2016103761A1 (ja) * 2014-12-22 2016-06-30 ジェイファーマ株式会社 癌の血中バイオマーカー

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11299489A (ja) 1998-04-22 1999-11-02 Japan Science & Technology Corp 中性アミノ酸トランスポーター及びその遺伝子
JP2000157286A (ja) 1998-09-03 2000-06-13 Japan Science & Technology Corp アミノ酸輸送蛋白及びその遺伝子
JP2005265531A (ja) 2004-03-17 2005-09-29 Tama Tlo Kk 中性アミノ酸トランスポーターによる癌の検出法、及びそのためのキット
WO2005121787A2 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462459B2 (en) * 2004-01-30 2008-12-09 Xenoport, Inc. LAT1 transporters expressed in blood brain barrier cells
US20090012024A1 (en) * 2005-07-26 2009-01-08 Procure Therapeutics Limited Stem Cell Markers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11299489A (ja) 1998-04-22 1999-11-02 Japan Science & Technology Corp 中性アミノ酸トランスポーター及びその遺伝子
JP2000157286A (ja) 1998-09-03 2000-06-13 Japan Science & Technology Corp アミノ酸輸送蛋白及びその遺伝子
JP2005265531A (ja) 2004-03-17 2005-09-29 Tama Tlo Kk 中性アミノ酸トランスポーターによる癌の検出法、及びそのためのキット
WO2005121787A2 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2146208A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012163332A (ja) * 2011-01-28 2012-08-30 J-Pharma Co Ltd 胃癌の悪性度診断用キット
JP2015134778A (ja) * 2015-02-06 2015-07-27 ジェイファーマ株式会社 抗ヒトｌａｔ１モノクローナル抗体及び前立腺がんの悪性度判定キット
JP2018509618A (ja) * 2015-03-11 2018-04-05 ジェイファーマ株式会社 前立腺癌の悪性度を決定するためのキット及び方法

Also Published As

Publication number Publication date
EP2977761A1 (en) 2016-01-27
JPWO2008096416A1 (ja) 2010-05-20
EP2146208A1 (en) 2010-01-20
EP2146208A4 (en) 2010-09-01
US20100112596A1 (en) 2010-05-06
CN101680895A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
WO2008096416A1 (ja) 前立腺がんの悪性度判定キット及びその方法
Rosen et al. Recent advances in magnetic resonance neurospectroscopy
WO2006135628A3 (en) Cytological methods for detecting a disease condition such as malignancy by raman spectroscopic imaging
WO2007081767A3 (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
WO2006047483A3 (en) Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
WO2008063479A3 (en) Pancreatic cancer biomarkers
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
WO2007093657A3 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
WO2006012646A3 (en) Amacr cancer markers
MX341191B (es) Metodos y composiciones para diagnostico y prognosis de lesion renal y falla renal.
BR112012032537B8 (pt) Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
EP2829881A3 (en) Diagnostic for colorectal cancer
EP2518509A3 (en) Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP.
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2009037635A3 (en) Method for the analysis of breast cancer disorders
WO2012178188A3 (en) Molecular diagnostic panel of eosinophilic gastrointestinal disorders
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2007048978A3 (fr) Procede de detection du cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2014100717A3 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2009099561A3 (en) Urinary ca125 peptides as biomarkers of ovarian cancer
WO2012104585A3 (en) Diagnostic method
EP2415877A3 (en) Means and methods for diagnosing pancreatic cancer
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2007048076A3 (en) Method for the diagnosis and prognosis of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780052524.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07713854

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008556938

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007713854

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12526062

Country of ref document: US